ATE363907T1 - Verfahren zur behandlung von multipler sklerose - Google Patents

Verfahren zur behandlung von multipler sklerose

Info

Publication number
ATE363907T1
ATE363907T1 AT04806691T AT04806691T ATE363907T1 AT E363907 T1 ATE363907 T1 AT E363907T1 AT 04806691 T AT04806691 T AT 04806691T AT 04806691 T AT04806691 T AT 04806691T AT E363907 T1 ATE363907 T1 AT E363907T1
Authority
AT
Austria
Prior art keywords
multiple sclerosis
meca
treating multiple
a3rag
apnea
Prior art date
Application number
AT04806691T
Other languages
English (en)
Inventor
Pnina Fishman
Yehuda Sara Bar
Lea Madi
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of ATE363907T1 publication Critical patent/ATE363907T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Sewing Machines And Sewing (AREA)
  • Steroid Compounds (AREA)
AT04806691T 2003-12-29 2004-12-23 Verfahren zur behandlung von multipler sklerose ATE363907T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53271203P 2003-12-29 2003-12-29

Publications (1)

Publication Number Publication Date
ATE363907T1 true ATE363907T1 (de) 2007-06-15

Family

ID=34738826

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04806691T ATE363907T1 (de) 2003-12-29 2004-12-23 Verfahren zur behandlung von multipler sklerose

Country Status (10)

Country Link
US (1) US7465715B2 (de)
EP (1) EP1699459B1 (de)
JP (1) JP2007517019A (de)
CN (1) CN100423723C (de)
AT (1) ATE363907T1 (de)
DE (1) DE602004006895T2 (de)
DK (1) DK1699459T3 (de)
ES (1) ES2287804T3 (de)
PL (1) PL1699459T3 (de)
WO (1) WO2005063246A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
ES2309817T3 (es) 2004-12-02 2008-12-16 Can-Fite Biopharma Ltd. Tratamiento de inflamacion.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (de) 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
EP1903044A1 (de) * 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
PT2137202T (pt) 2007-03-14 2017-10-02 Can-Fite Biopharma Ltd Processo para a síntese de ib-meca
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
IL200753A (en) 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
US20140194308A1 (en) * 2011-04-22 2014-07-10 Kyoto University Use of myelin basic protein as a novel genetic factor for rheumatoid arthritis
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
WO2013111132A1 (en) * 2012-01-23 2013-08-01 Can-Fite Biopharma Ltd. Treatment of liver conditions
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN109310695B (zh) * 2016-04-21 2022-04-01 阿斯特罗赛特制药公司 治疗神经和心血管病况的化合物和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5773423A (en) * 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CZ294538B6 (cs) * 2002-12-30 2005-01-12 Ústav Experimentální Botaniky Akademie Vědčeské Re Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující

Also Published As

Publication number Publication date
JP2007517019A (ja) 2007-06-28
EP1699459B1 (de) 2007-06-06
US20060142237A1 (en) 2006-06-29
WO2005063246A1 (en) 2005-07-14
ES2287804T3 (es) 2007-12-16
DE602004006895D1 (de) 2007-07-19
DK1699459T3 (da) 2007-10-08
CN100423723C (zh) 2008-10-08
US7465715B2 (en) 2008-12-16
DE602004006895T2 (de) 2008-01-31
PL1699459T3 (pl) 2007-12-31
EP1699459A1 (de) 2006-09-13
CN1901915A (zh) 2007-01-24

Similar Documents

Publication Publication Date Title
DE602004006895D1 (de) Verfahren zur behandlung von multipler sklerose
MY146986A (en) Methods for treating interleukin-6 related diseases
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
MX2023002321A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
DE602004024374D1 (de) Zusammensetzungen zur verwendung als protein-kinase-inhibitoren
AU2003225800A1 (en) Azolylaminoazine as inhibitors of protein kinases
EA200501817A1 (ru) Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
EP1064966A3 (de) Zusammensetzungen von 5HT1-Rezeptor -Antagonisten, Koffein und COX-2 Inhibitoren zur Behandlung von Migräne
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
WO2003093503A3 (en) Method for bioequivalence determination using expression profiling
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
WO2003094957A3 (en) Methods of therapy for inducing tolerance
AP2004003082A0 (en) Pharmaceutical combinations of adenosine A-2A and beta-2- adrenergic receptor agonists
MX2007005525A (es) Tratamiento terapeutico de resorcion ose acelerada.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1699459

Country of ref document: EP

REN Ceased due to non-payment of the annual fee